[123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism

Schizophrenia Research

Volumn 139, Issue 1-3, 2012, Pages 40-45

  Tinazzi, Michele ^a   Cipriani, Andrea ^a   Matinella, Angela ^a   Cannas, Antonino ^b   Solla, Paolo ^b   Nicoletti, Alessandra ^c   Zappia, Mario ^c   Morgante, Letterio ^d   Morgante, Francesca ^d   Pacchetti, Claudio ^e   Sciarretta, Massimo ^e   Dallocchio, Carlo ^f   Rossi, Simone ^g   Malentacchi, Maria ^g   Ceravolo, Roberto ^h   Frosini, Daniela ^h   Sestini, Stelvio ⁱ   Bovi, Tommaso ^a   Barbui, Corrado ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f Unit of Neurology   (Italy)

^g UNIVERSITY OF SIENA   (Italy)

^h UNIVERSITY OF PISA   (Italy)

ⁱ Hospital of Prato   (Italy)

Author keywords

123I FP CIT SPECT; Antipsychotics; Dopamine receptors; Parkinsonism; Schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; IOFLUPANE I 123; NEUROLEPTIC AGENT; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DIAGNOSTIC AGENT; TROPANE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; DEMOGRAPHY; DRUG INDUCED DISEASE; DRUG INDUCED PARKINSONISM; DRUG USE; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; BRAIN MAPPING; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; NONPARAMETRIC TEST; PARKINSON DISEASE; PATHOPHYSIOLOGY; SCINTISCANNING; SEX DIFFERENCE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN MAPPING; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; SCHIZOPHRENIA; SEX FACTORS; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84863781344     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.06.003     Document Type: Article

References (26)

1. 123I]FP-CIT SPET Study Group. Mov. Disord. 2000, 15:503-510.
2. 123I]FP-CIT SPECT. J. Nucl. Med. 1999, 40:753-761.
3. Burn D.J., Brooks D.J. Nigral dysfunction in drug-induced parkinsonism: an 18-F-dopa PET study. Neurology 1993, 43:552-556.
4. Chang L.T. A method for attenuation correction in radionuclide computed tomography. IEEE Trans. Nucl. Sci. 1978, 25:638-643.
5. Darcourt J., Booij J., Tatsch K., Varrone A., Vander Borght T., Kapucu O.L., Någren K., Nobili F., Walker Z., Van Laere K. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur. J. Nucl. Med. 2010, 37(2):443-450.
6. Hardie R.J., Lees A.J. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J. Neurol. Neurosurg. Psychiatry 1988, 51:850-854.
7. Hassin-Baer S., Sirota P., Korczyn A.D., Treves T.A., Epstein B., Shabtai H., Martin T., Litvinjuk Y., Giladi N. Clinical characteristics of neuroleptic-induced parkinsonism. J. Neural Transm. 2001, 108:1299-1308.
8. Hausner R.S. Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment. J. Clin. Psychiatry 1983, 1:13-16.
9. Jankovic J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 2008, 79:368-376.
10. Jankovic J., Casabona J. Coexistent tardive dyskinesia and parkinsonism. Clin. Neuropharmacol. 1987, 10:511-521.
11. Janno S., Holi M., Tuisku K., Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am. J. Psychiatry 2004, 161:160-163.
12. Kägi G., Bhatia K.P., Tolosa E. The role of DAT-SPECT in movement disorders. J. Neurol. Neurosurg. Psychiatry 2010, 81:5-12.
13. Leucht C., Heres S., Kane J.M., Kissling W., Davis J.M., Leucht S. Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 2011, 127(1-3):83-92.
14. 123I] FP-CIT SPET imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov. Disord. 2006, 21:510-514.
15. Miller L.G., Jankovic J. Metoclopramide-induced movement disorders. Arch. Intern. Med. 1989, 149:2486-2492.
16. Modestin J., Stephan P.L., Erni T., Umari T. Prevalence of extrapyramidal symptoms in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr. Res. 2000, 42:223-230.
17. Modestin J., vogt Wehrli M., Stephan P.L., Agarwalla P. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. Schizophr. Res. 2008, 100:97-107.
18. Muscettola G., Barbato G., Pampallona S., Casiello M., Bollini P. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J. Clin. Psychol. 1999, 19:203-208.
19. Reader T.A., Ase A.R., Huang N., Herbert L., van Gelder N.M. Neuroleptics and dopamine transporters. Neurochem. Res. 1998, 23:73-80.
20. Richardson M.A., Craig T.J. The coexistence of parkinsonism-like syndrome and tardive dyskinesia. Am. J. Psychiatry 1982, 139:341-343.
21. Scherfler C., Nocker M. Dopamine transporter SPECT: how to remove subjectivity?. Mov. Disord. 2009, 24:721-724.
22. Susatia F., Fernandez H.H. Drug-induced parkinsonism. Curr. Treat. Options Neurol. 2009, 11:162-169.
23. 123I] FP-CIT SPET imaging in drug-induced parkinsonism. Mov. Disord. 2008, 23(13):1825-1829.
24. 123I] FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J. Neurol. 2009, 256:910-915.
25. Tolosa E., Coelho M., Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov. Disord. 2003, 18(Suppl. 7):28-33.
26. Valvhar M., Hanbauer I. Comparison of 3-H-WIN 35,428 binding, a marker for dopamine transport, in embryonic mesencephalic neuronal cultures with striatal membranes of adult rats. J. Neurochem. 1993, 60:469-476.